Clinical trials: Type 2 Diabetes (T2D)
Healthy
Evaluate the Pharmacokinetics of Digoxin When Coadministered With PEX168 in Healthy Adult Subjects
To assess the effect of PEX168 doses on the pharmacokinetics of digoxin in healthy subjects.To provide a scientific basis for clinical drug combination of PEX168.
- Trial name
- NCT02472236
- Testing
- PEX168, Digoxin
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Type 2 Diabetes Mellitus
A Study to Evaluate AZP531 in Healthy Volunteers, Overweight/Obese Volunteers and Patients With Type 2 Diabetes Mellitus
Objectives: Primary Objectives To investigate the safety and tolerability of single ascending doses of AZP- 531 in healthy volunteers.
- Trial name
- NCT02040012
- Testing
- AZP-531
- Where
- United Kingdom
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Alizé Pharma
Diabetes Mellitus, Type 2
4 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 Diabetes
Primary objective: safety and tolerability of BI 10773 in male and female patients with type 2 diabetes Secondary objective: pharmacokinetics and pharmacodynamics of BI 10773
- Trial name
- NCT00558571
- Testing
- BI 10773 low dose, BI 10773 medium dose, BI 10773 high dose
- Where
- 3 sites in Germany
- Volunteers
- 78 people
- Sponsor
- Boehringer Ingelheim
Diabetes Type 2
Clamp Study Comparing Inhalation of Technosphere®/Insulin in Smokers and Non-Smokers With Type 2 Diabetes
Twelve smoking and twelve non-smoking subjects with Type 2 Diabetes Mellitus will be enrolled in this study to determine the effect of Technosphere® Insulin Inhalation Powder on insulin in the body during a clamp procedure.
- Trial name
- NCT00934414
- Testing
- Technosphere Insulin Inhalation Powder
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Mannkind Corporation
Diabetes Mellitus, Type 2
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 135585 XX in Patients With Type 2 Diabetes
The objective of this study is to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of BI 135585 XX following multiple dose administration over 14 days
- Trial name
- NCT01282970
- Testing
- BI 135585
- Where
- Germany
- Volunteers
- 72 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2, Obesity
Prevalence and Overlap of Cardiovascular, Kidney, and Metabolic Diseases in Korea: A Population-based Study
This study tests the prevalence and characteristics of overlapping obesity, type 2 diabetes (T2D), cardiovascular disease (CVD), chronic kidney disease (CKD), and metabolic dysfunction-associated steatotic liver disease…
- Conditions
- Diabetes Mellitus, Type 2, Obesity, Chronic Kidney Disease, Cardiovascular Risk
- Trial name
- NCT07673822
- Testing
- No treatment given
- Where
- South Korea
- Volunteers
- 800,000 people
- Sponsor
- Novo Nordisk A/S
Angina Pectoris, Coronary Artery Disease
A Study on the Effects of Ranolazine on Exercise Duration in Subjects With Chronic Stable Angina and Coronary Artery Disease (CAD) With Type 2 Diabetes Mellitus (T2DM)
This study will evaluate the efficacy of ranolazine compared to placebo on duration of exercise assessed by exercise tolerance testing (ETT) at anticipated peak ranolazine plasma concentration after 12 weeks of treatment in…
- Conditions
- Angina Pectoris, Coronary Artery Disease, Type 2 Diabetes Mellitus
- Trial name
- NCT01334203
- Testing
- Ranolazine
- Sponsor
- Gilead Sciences
Diabetes Mellitus Type 2, GI Side Effect
Glucophage XR® Observational Study
This is a non-interventional, prospective study where no visits or additional interventions to the daily practice of the physician will be performed.
- Trial name
- NCT01336673
- Where
- Thailand
- Volunteers
- 518 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Diabetes Mellitus, Type 2
Comparison of Nutritional Products for People With Type 2 Diabetes
Compare the glycemic and insulinemic responses of a standard nutritional product with two diabetes-specific nutritional products in patients with type 2 diabetes.
- Trial name
- NCT00797069
- Testing
- standard nutritional product (medical food), nutritional product for diabetes (medical food), diabetes specific experimental nutritional product (medical food)
- Where
- 3 sites in Spain
- Volunteers
- 58 people
- Sponsor
- Abbott Nutrition
Diabetes (Insulin-requiring, Type 1 or Type 2)
Safety and Efficacy of the Fully Closed Loop iLet Bionic Pancreas in Adults With Type 1 and Type 2 Diabetes
The goal of this clinical trial is to evaluate the safety and efficacy of the fully closed loop (FCL) iLet automated insulin delivery (AID) System in people ≥18 years old with type 1 diabetes or type 2 diabetes requiring insulin…
- Trial name
- iLet FCL (NCT07911566)
- Testing
- iLet FCL
- Volunteers
- 400 people
- Sponsor
- Beta Bionics, Inc.
Type 2 Diabetes Mellitus
Study Of Denagliptin In Subjects With Type 2 Diabetes Mellitus (T2DM)
GW823093 is a selective DPP-IV Inhibitor and is being investigated as a once a day oral therapy. The purpose of the Study is to evaluate the effectiveness, safety, and tolerability of 2 doses of GW823093, compared to placebo…
- Trial name
- NCT00387972
- Testing
- denagliptin (GW823093)
- Where
- 57 sites in United States
- Sponsor
- GlaxoSmithKline
Pre-diabetes
Evaluation of Video On-Demand Programming to Prevent Type 2 Diabetes in Adults
Over the past 40 years, diabetes has increased dramatically in parallel with rapid increases in obesity.About 90 to 95% of persons with diabetes have type 2 diabetes, which begins when the body becomes resistant to the hormone…
- Trial name
- Project NOT ME (NCT01768546)
- Testing
- Virtual Diabetes Prevention Program, Interactive tracking and problem solving web portal
- Volunteers
- 306 people
- Sponsor
- UnitedHealth Group
Type 2 Diabetes
Single Ascending Dose Study With Healthy Male Volunteers and Type II Diabetic Patients
The purpose of this study is to assess safety and tolerability of AZD6714 after single ascending oral doses in healthy male subjects and type 2 diabetic patients.
- Trial name
- NCT00886366
- Testing
- AZD6714
- Where
- Sweden
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus (T2DM)
Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCL 25mg/5mg/1000mg Extended-Release Tablets Versus Trijardy® XR Extended Release Film Coated Tablets
Randomized, Single Oral Dose, Two-period, Two Sequence, Open-label, Crossover, Bioequivalence Study to Compare Empagliflozin-Linagliptin-Metformin XR Tablet 25mg/ 5mg/1000mg (25mg Empagliflozin /5mg Linagliptin /1000mgMetformin…
- Trial name
- NCT07213895
- Testing
- Empagliflozin/Linagliptin/Metformin HCL, Trijardy® XR Extended release film coated tablets
- Where
- Jordan
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Type 2 Diabetes, Hypertension
A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THP-00102, and THP-00103 in Subjects With T2DM and Essential Hypertension
[Primary Objective] To demonstrate the superiority of the change in mean sitting systolic blood pressure (MSSBP) and hemoglobin A1c (HbA1c)on week 12 of the combination therapy of THP-00101 (dapagliflozin 10 mg) and THP-00102…
- Trial name
- THP-001-031 (NCT06647745)
- Testing
- THP-00101, THP-00102, THP-00103
- Where
- 2 sites in South Korea, Thailand
- Volunteers
- 221 people
- Sponsor
- THPharm Corp.
Diabetic Neuropathies, Diabetes Mellitus, Insulin-Dependent
Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes
The purpose of this protocol is to determine if an investigational drug is effective in treating nerve malfunction in diabetes.
- Conditions
- Diabetic Neuropathies, Diabetes Mellitus, Insulin-Dependent, Diabetes Mellitus, Non-Insulin-Dependent
- Trial name
- NCT00044395
- Testing
- Ruboxistaurin mesylate
- Where
- 39 sites in United States, Australia and 7 more
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
Colesevelam for Children With Type 2 Diabetes
This study will evaluate the efficacy and safety of the study drug in treating type 2 diabetes in children 10 to 17 years old. The groups will be low-dose (0.625 g Welchol) and high-dose (3.75 g Welchol).
- Trial name
- WELKid DM (NCT01258075)
- Testing
- High-dose colesevelam, Low-dose colesevelam
- Where
- 24 sites in United States
- Volunteers
- 236 people
- Sponsor
- Daiichi Sankyo
Diabetes Mellitus, Non-Insulin-Dependent
Study to Assess the Efficacy and Safety of Sitagliptin Added to the Regimen of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (0431-189)
After 24 weeks of treatment, to assess the A1C-lowering efficacy of sitagliptin 100 mg once daily added to the regimen of patients with inadequate glycemic control on metformin monotherapy
- Trial name
- NCT00875394
- Testing
- sitagliptin phosphate, Comparator: metformin, Comparator: Antidiabetic Standard of Care
- Volunteers
- 68 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetic Gastroparesis
Diabetic Gastroparesis Efficacy/Safety Study of TZP-102
The purpose of this study is to test the safety and effectiveness of 10 mg TZP-102 given prior to meals three times a day compared to placebo (capsule that looks like active study drug but contains no active drug), administered…
- Trial name
- DIGEST (NCT01664637)
- Testing
- 10 mg TZP-102
- Where
- 35 sites in United States, Poland
- Volunteers
- 120 people
- Sponsor
- Tranzyme, Inc.
Diabetes
Glycemic Response to Two Enteral Formulas in Persons With Type 2 Diabetes Mellitus
This will be a randomized, cross-over design. Subjects will be randomized to one of two interventions on two separate study days, 1 week apart.
- Trial name
- NCT02898766
- Testing
- Enteral Nutrition Formula
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Société des Produits Nestlé (SPN)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.